Preview

Obesity and metabolism

Advanced search

Urinary C Peptide/ Creatinine Ratio Is Related to Insulin Resistance but Not Vascular Complications In Type 2 Diabetes

https://doi.org/10.14341/omet13246

Contents

Scroll to:

Abstract

BACKGROUND. Insulin resistance (IR) is considered the main mechanism of type 2 diabetes (T2DM). Diabetic vascular complications (DVC) are main causes of morbidity and mortality. Urinary c-peptide to creatinine ratio (UCPCR) is a novel promising biomarker that may be of value in assessment of IR and DVC.

AIM. The present work aimed at studying the relation between UCPCR, IR and DVC in subjects with T2DM.

MATERIALS AND METHODS. This was a cross-sectional study performed on a group of subjects with T2DM. Insulin resistance was assessed by measuring homeostasis model assessment for insulin resistance (HOMA-IR). Laboratory investigations included glycemic parameters and renal functions. Human C-peptide ELISA kit was used to asses c-peptide level in a spot urine sample after processing.

RESULTS. The study included 90 subjects with T2DM. There was highly statistically significant positive correlations between UCPCR and HOMA-IR, FPG and HbA1c with P values of <0.001, 0.006 and 0.005 respectively. FPG, HbA1c, and UCPCR were the independent risk factors for IR in the univariate regression analysis. However, UCPCR was the only independent risk factor for IR in multivariate analysis (OR 16.431(1.401–192.706). UCPCR cut-off value (>0.19) nmol/mmol was able to differentiate significantly (p<0.001) between patients with IR and those without IR with good sensitivity, specificity and AUC (85.11%, 60.47% and 0.716 respectively).

CONCLUSION. In patients with T2DM, UCPCR could be used as a simple, noninvasive and available biomarker for IR. It also could be used as a marker of glycemic control. However, UCPCR is not related to DVC.

For citations:


Eman Y.M., Noha G.A., Yasmine A.I., Rowan K., Heba S.K. Urinary C Peptide/ Creatinine Ratio Is Related to Insulin Resistance but Not Vascular Complications In Type 2 Diabetes. Obesity and metabolism. 2026;23(2):61-66. https://doi.org/10.14341/omet13246

RATIONALE

Type 2 diabetes (T2DM) is a highly prevalent disease with a global social and economic burden. Its accompanied vascular complications represent a major cause of morbidity and mortality worldwide. T2DM is an expanding disease with rapidly increasing incidence due to the obesity pandemic which is closely related to T2DM [1].

This link between obesity and T2DM is mediated through insulin resistance (IR). Visceral adipose tissue is considered an endocrinal organ secreting various types of adipokines. These adipokines play a pivotal role in the development of IR and subclinical inflammations which represent the main mechanism of T2DM [2][3].

Early detection of IR could help in improving patients' outcome and delaying the development of chronic complications. Additionally, IR is the most powerful predictor of T2DM development and also a major therapeutic target in treatment of T2DM. However, measurement of IR faces some difficulties [4].

The gold standard for measurement of IR is the hyperinsulinemic euglycemic clamp technique which is technically demanding and time consuming. Numerous surrogate marker of IR have been emerged but none of them proved to be an ideal biomarker. Homeostasis model assessment for insulin resistance (HOMA-IR) is the most commonly used surrogate marker of IR. However, no standard cut off value could be generalized [5][6].

Serum c-peptide level is a gold standard measurement of endogenous insulin secretion. It has been found that serum c-peptide is strongly correlated to urinary c-peptide and urinary c-peptide to creatinine ratio (UCPCR). Thus, UCPCR could be used as a valuable non- invasive marker of endogenous insulin secretion and IR in patients with T2DM [7][8]. Recently, low UCPCR was able to identify people with type 1 diabetes (T1DM) with exceptional sensitivity and specificity making it a cost effective, non-invasive marker of T1DM [9]. UCPCR was also identified as an independent risk factor of coronary artery disease in this cohort [10].

AIM OF THE STUDY

The present work aimed at studying the relation between UCPCR, IR and DVC in subjects with T2DM.

MATERIALS AND METHODS

Site and time of the study

Study site. Included subjects were recruited from diabetes outpatient clinic of Alexandria Main University Hospital, Alexandria, Egypt.

Time of the study. The present study was performed between March 2023 till September 2023.

Study populations

Population: The present study included 90 subjects with T2DM.

Inclusion criteria: Males or females, diagnosed with T2DM, above the age of 18 years.

Exclusion criteria: Severe renal impairment (eGFR <15 ml/min/1.73), subjects with urinary tract infection, pregnant and lactating females.

Sampling method from the study population (or several sampling methods from several study populations)

Sampling was done randomly.

Study design

The present study is a single-center, observational, cross sectional study including one study population.

Sample size calculation

Based on the study of Wang et al, [8] a minimal required sample size of 36 patients with T2DM is needed to assess UCPCR in patients with T2DM and its relation to IR and vascular complications that detect a difference of .3 between the null hypothesis correlation of 0.5 and the alternative hypothesis correlation of 0.78, using One Correlation Power Analysis that achieves 80% power with a target significance level at 5%. Sample size was calculated using NCSS 2004 and PASS 2000 program.

Methods

A detailed history was taken from each participant including age, diabetes duration, smoking and drug history. Physical examination was performed including measuring blood pressure, waist circumference, weight and height from which body mass index (BMI) was calculated [11][12].

Detailed neurological examination was done and diabetic peripheral neuropathy (DPN) was diagnosed as per American Diabetes Association (ADA) recommendations [13].

Peripheral arterial disease (PAD) was diagnosed by calculating ankle brachial index (ABI). Measuring systolic pressure of dorsalis pedis (DP)and posterior tibial (PT) arteries in each lower limb was done with Doppler examination and sphygmomanometer cuff. Calculation of the ABI was done by dividing the higher pressure of the DP and the PT arteries by the higher systolic pressure of the two brachial arteries. The lower value of the two calculated ABI values was used for analysis [14].

Fundus examination was done for each subject using slit lamp biomicroscope plus fundus lens by expert ophthalmologist in the ophthalmology outpatient clinic to diagnose diabetic retinopathy (DR).

Laboratory investigations were done after overnight fasting for measurement of: fasting plasma glucose (FPG), fasting insulin and serum creatinine. A spot urine sample was collected for measurement of urinary albumin to creatinine ratio (UACR) and UCPCR.

IR was calculated from FPG and fasting insulin by measuring HOMA-IR using the equation (HOMA-IR = fasting glucose (mg/dL) X fasting insulin (mU/L) / 405) [15].

Estimated glomerular filtration rate was calculated from serum creatinine using CKD-EPI equation. Diabetic kidney disease (DKD) was diagnosed by the presence of albuminuria (UACR≥30 mg/g) and/or eGFR <60 ml/min/1.73 m² [16].

UCPCR was measured from a spot urine sample collected in aseptic tube, centrifuged for 20 min at 2.000–3.000 rpm and the supernatant was collected. Human C-peptide ELISA kit was used to assess c-peptide level in the processed urine sample [17].

Statistical analysis

Data were analyzed using IBM SPSS software package version 20.0 (Armonk, NY: IBM Corp, released in 2011). Qualitative data were described using number and percent. Quantitative data were described using mean and standard deviation. Significance of the obtained results was judged at the 5% level. Mann Whitney test was used for analysis of non-normally distributed quantitative variables, to compare between two studied groups. Spearman coefficient was used to correlate between two quantitative variables. Regression analysis was done to detect the most independent factor for IR. Receiver operating characteristic curve (ROC) was generated by plotting sensitivity (TP) on Y axis versus 1-specificity (FP) on X axis at different cut off values. The area under the ROC curve (AUC) denotes the diagnostic performance of the test. Area more than 50% gives acceptable performance and area about 100% is the best performance for the test.

Ethical expert review

The study was conducted according to the ethical standards of the Helsinki Declaration. Approval of the ethical committee of Faculty of Medicine, Alexandria University was obtained (IRB number 00012089) (date: 16/6/2022). Each participant gave a written informed consent before inclusion in the study.

RESULTS

The present study included 90 subjects with T2DM with mean age of 54.91±8.93 years. Thirty six subjects were males while the rest 54 subjects were females. Baseline characteristics of the studied subjects are shown in table 1. Regarding the distribution of vascular complications among the total sample, 17 patients (18.9%) had DN, 30 patients (33.3%) had DKD and 27 patients (30%) had DR and 44 patients (48.9%) had PAD. There were no statistically significant differences in the mean value of UCPCR between subjects with vascular complications (PVD, DN, DKD, and DR) and those without complications.

Table 1: Baseline characteristics of the studied subjects (n=90)

 

Mean ± SD

Age (years)

54.91 ± 8.93

Gender

Male

Female

36 (40%)

54 (60%)

Smoking

19 (21.1%)

Hypertension

45 (50%)

Diabetes duration (years)

9.87±7.06

BMI (kg/m²)

33.14±5.61

Waist circumference (cm)

111.7±12.27

Systolic BP (mmHG)

133.6±17.82

Diastolic BP (mmHG)

84.89±11.14

ABI

1.18±0.28

FPG (mg/dl)

147.1±67.42

F. insulin(μU/mL)

7.87±4.24

HOMA-IR

2.71±1.59

HbA1c (%)

8.73±2.36

Creatinine (mg/dl)

0.80±0.36

e-GFR (ml/min/1.7)

96.64±20.95

UACR (mg/g)

76.61±178.5

UCPCR (nmol/mmol)

0.32±0.23

BMI: Body mass index, BP: blood pressure; ABI: Ankle brachial index, FPG: Fasting plasma glucose; HOMA-IR: Homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; e-GFR: estimated glomerular filtration rate; UACR: Urinary albumin to creatinine ratio; UCPCR: Urinary c-peptide to creatinine ratio; SD: Standard deviation

There were highly statistically significant positive correlations between UCPCR and HOMA-IR, FPG and HbA1c with P values of <0.001, 0.006 >and 0.005 respectively. However, no significant correlations were detected between UCPCR and the rest of the studied parameters (Table 2) (Figure 1).

Table 2: Correlation between UCPCR with different parameters (n = 90)

 

Urinary c peptide / Creatinine ratio

rs

p

Age (years)

-0.030

0.782

Diabetes Duration (years)

-0.054

0.616

BMI (kg/m²)

-0.068

0.522

Waist circumference (cm)

-0.062

0.560

Systolic BP (mmHg)

0.154

0.148

Diastolic BP (mmHg)

0.093

0.381

ABI

-0.190

0.073

FPG (mg/dl)

0.289*

0.00⁶*

HOMA-IR

0.375*

<0.00¹*

HbA1c (%)

0.294*

0.00⁵*

Creatinine (mg/dl)

-0.075

0.484

e-GFR (ml/min/1.73 m²)

0.092

0.389

UACR (mg/g)

0.095

0.372

BMI: Body mass index, BP: blood pressure; ABI: Ankle brachial index, FPG: Fasting plasma glucose; HOMA-IR: Homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; e-GFR: estimated glomerular filtration rate; UACR: Urinary albumin to creatinine ratio
rs: Spearman coefficient *: Statistically significant at p ≤ 0.05.

Figure 1: Correlation between UCPCR with HOMA-IR (n=90)

On performing the logistic regression analysis for detecting parameters affecting IR (HOMA-IR ≥2.5); FPG, HbA1c, and UCPCR were the independent risk factors for IR in the univariate analysis. However, UCPCR was the only independent risk factor for IR in multivariate analysis (Table 3).

Table 3: Univariate and multivariate logistic regression analysis for the parameters affecting HOMA-IR ≥2.5 (no. ≥2.5 = 47 vs. 43)

 

Univariate

#Multivariate

p

OR (LL – UL 95%C.I)

p

OR (LL – UL 95%C.I)

Age (years)

0.323

0.976 (0.931–1.024)

  

Diabetes Duration (years)

0.524

0.981 (0.925–1.041)

  

BMI (kg/m²)

0.358

1.036 (0.961–1.117)

  

Waist circumference (cm)

0.864

0.997 (0.964–1.031)

  

Lower ABI

0.539

1.602 (0.357–7.187)

  

Systolic BP (mmHg)

0.696

1.005 (0.981–1.028)

  

Diastolic BP (mmHg)

0.132

1.031 (0.991–1.072)

  

FPG (mg/dl)

0.007*

1.012 (1.003–1.021)

0.085

1.008 (0.999–1.017)

HbA1c (%)

0.009*

1.303 (1.068–1.589)

0.305

1.127 (0.897–1.416)

e-GFR (ml/min/1.73 m²)

0.858

1.002 (0.982–1.022)

  

UACR (mg/g)

0.649

0.999 (0.997–1.002)

  

UCPCR (nmol/mmol)

0.009*

23.379 (2.161–252.92)

0.026*

16.431 (1.401–192.706)

BMI: Body mass index, ABI: Ankle brachial index, BP: blood pressure; FPG: Fasting plasma glucose; HbA1c: glycated hemoglobin; e-GFR: estimated glomerular filtration rate; UACR: Urinary albumin to creatinine ratio; UCPCR: Urinary c- peptide to creatinine ratio
OR: Odd`s ratio; C.I: Confidence interval; LL: Lower limit; UL: Upper Limit
#: All variables with p<0.05 was included in the multivariate
*: Statistically significant at p ≤ 0.05

ROC curve was performed to set the cut off value of UCPCR for diagnosis of IR. A cut off value of UCPCR (>0.19) nmol/mmol was able to differentiate significantly (p<0.001) between patients with IR and those without IR with good sensitivity, specificity and AUC (85.11%, 60.47% and 0.716 respectively) (Figure 2).

Figure 2: ROC curve for UCPCR to discriminate HOMA-IR ≥2.5 (n=47 vs. 43)

DISCUSSION

Representativeness of Samples

The study sample is representative to the studied population. Sample size calculation was done.

Comparison with other publications

UCPCR is an emerging promising biomarker for endogenous insulin secretion and IR. The current work uniquely studied this association and also the relation between UCPCR and DVC. Few previous studies investigated these relations and none of them was on Egyptian population.

The present study included 90 subjects with T2DM. The mean UCPCR of the studied subjects was (0.32±0.23 nmol/mmol).

Previous studies [18–20] demonstrated a highly variable range of UCPCR (0.43–2.47 nmol/mmol) in subjects with T2DM and a much lower values in subjects with T1DM. This wide range of UCPCR values across studies could be attributed to several factors including demographic and clinical data. Wang et al,[18] found a higher level of UCPCR in patients with T2DM and monogenic diabetes compared to T1DM. They also divided patients with T2DM into 2 groups regarding their UCPCR and they found that individuals with UCPCR ≤0.20 nmol/mmol had lower BMI, lower serum c-peptide and higher insulin use. Their cohort included higher males (64%) in T2DM group than in our cohort (40%). Besser et al. [19] also differentiated between T2DM, MODY and T1DM using UCPCR. A level of 4.01 (2.84–5.74) nmol/mmol for UCPCR was identified in patients with T2DM. This discrepancy between their results and our results may be due to younger population in Besser et al study (<21 years) than our cohort (54.91±8.93 years). Bhosle et al, [20] concluded that UCPCR can be used to evaluate islets β Cell function in T2DM patients with different renal function status and set a cut-off (UCPCR ≤1.13 nmol/g) for identifying severe insulin deficiency in T2DM patients. Moreover, ethnicity, diabetes duration, age and gender play a crucial role in this variation. Urinary c-peptide excretion declines with increasing age. Furthermore, females have higher values of UCPCR due to lower muscle mass compared to males.

In the current study, the mean value of UCPCR showed a highly statistically significant positive correlation with HOMA-IR in subjects with T2DM. Additionally, UCPCR was the only independent predictor of IR in multivariate regression analysis. HOMA-IR is the most commonly used surrogate marker of IR. Previous studies demonstrated its association with glycemic control, metabolic profile and vascular complications [21].

Wang et al, [8] in concordance with the results of the present study, found a strong positive correlation between UCPCR and HOMA-IR in 1299 hospitalized Chinese subjects with T2DM. Furthermore, Zhou et al, [20] showed a positive correlation between UCPCR and HOMA-IR. Few more studies demonstrated a positive correlation between UCPCR and HOMA-IR in healthy individuals [22][23], prediabetes [22], and metabolic syndrome [24]. However, in Egypt, only two previous studies [25][26] discussed the correlation between UCPCR and HOMA-IR. Both cohorts included children with obesity and both showed positive correlations between UCPCR and HOMA-IR in obese children.

The present study could set a cut-off value of (>0.19) nmol/mmol for UCPCR to predict IR in patients with T2DM. By far, this is the first study to detect a cut-off value of UCPCR for detection of IR in patients with T2DM. Additionally, the present study uniquely studied the relation between UCPCR and IR in Egyptian population with T2DM.

The current work, additionally, found a significant positive correlation between UCPCR and FPG. In addition, FPG was detected as an independent risk factor for IR in univariate but not multivariate analysis. An Indian study by Kulkarni et al [27] showed similar results. They suggested that urinary c-peptide and UCPCR could be used as predictors of endogenous insulin secretion. Thus, they concluded that UCPCR could predict glycemic control in subjects with T2DM. Gedam et al [24] and Reinter et al [22] also reported a significant positive correlation between UCPCR and FPG in studied participants.

Regarding the relation between UCPCR and HbA1c, the present work revealed a significant positive correlation between them. HbA1c also was detected as an independent risk factor for IR in univariate but not multivariate analysis. No previous studies were detected concerning the relation between UCPCR and HbA1c in T2DM. However, Hassan et al [25] found similar results but in obese children with IR. Moreover, Reinter et al [22] reported the same correlation in healthy individuals. However, Elzahar et al [28] showed a significant negative correlation between UCPCR and HbA1c in children with T1DM and T2DM. This discordance may arise from the use of different cohort with different age and type of diabetes.

The present work also studied the relation between UCPCR and DVC. Results revealed that there is no relation between UCPCR and DVC (DKD, DR, DN and PAD). In disagreement with these results Wang et al [8] found that UCPCR is an independent risk factor of DKD in univariate and multivariate analysis. This discordance between their results and ours could be attributed to the small number of subjects in each complication subgroup in the present study. Thus, further studies with larger sample size are encouraged to demonstrate this relation clearly.

Clinical significance of results

UCPCR was highly statistically significantly correlated to IR and glycemic parameters but not DVC in patients with T2DM.

Study limitations

The present study was a single center study. When the studied subjects were divided according to DVC, a small number of subjects was present in each group which resulted in non significant results regarding the relation between UCPCR and DVC.

Next studies

Further studies are required to assess the relation between UCPCR and DVC. Multicenter studies on larger sample size and different study population are needed to generalize the results of the present study.

CONCLUSION

The present study demonstrated a strong association between UCPCR and IR in patients with T2DM. This suggests that UCPCR could be used as a simple, noninvasive and available biomarker for IR in T2DM. UCPCR could be a predictor of endogenous insulin secretion and diabetes control as it showed a strong significant correlation with FPG and HbA1c. However, the present study found no relation between UCPCR and VDC which will need further studies with larger sample size to identify this relation.

ADDITIONAL INFORMATION

Funding. No funding.

Conflict of interest. The authors declare no obvious and potential conflicts of interest related to the content of this article.

Contribution of authors. Eman Y Morsy — Substantial contributions to the conception and design of the work; acquisition, analysis, interpretation of data for the work; and Drafting the work and revising it critically for important intellectual content. Noha G Amin — Substantial contributions to the conception and design of the work; acquisition, analysis, interpretation of data for the work; and Drafting the work and revising it critically for important intellectual content. Yasmine A Issa — Substantial contributions to the conception and design of the work; acquisition, analysis, interpretation of data for the work; and Drafting the work and revising it critically for important intellectual content. Rowan KA Khalifa — Substantial contributions to the conception and design of the work; acquisition, analysis, interpretation of data for the work; and Drafting the work and revising it critically for important intellectual content. Heba S Kassab — Substantial contributions to the conception and design of the work; acquisition, analysis, interpretation of data for the work; and Drafting the work and revising it critically for important intellectual content.

All of the authors read and approved the final version of the manuscript before publication, agreed to be responsible for all aspects of the work, implying proper examination and resolution of issues relating to the accuracy or integrity of any part of the work.

Acknowledgment. We would like to acknowledge Diabetes and Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University where the work was done.

References

1. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015;1(1):1-22. doi: https://doi.org/10.1038/nrdp.2015.19.

2. Viner R, Segal T, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Archives of disease in childhood. 2005;90(1):10-4. doi: https://doi.org/10.1136/adc.2003.036467

3. Cho M, Park JS, Nam J, et al. Association of abdominal obesity with atherosclerosis in type 2 diabetes mellitus (T2DM) in Korea. Journal of Korean medical science. 2008;23(5):781-8. doi: https://doi.org/10.3346/jkms.2008.23.5.781

4. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The lancet. 2017;389(10085):2239-51. doi: https://doi.org/10.1016/S0140-6736(17)30539-1

5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology-Endocrinology and Metabolism. 1979;237(3):E214. doi: https://doi.org/10.1152/ajpendo.1979.237.3.E214

6. Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: http://dx.doi.org/10.18535/jmscr/v4i9.65

7. Jones AG, Besser R, McDonald TJ, et al. Urine C‐peptide creatinine ratio is an alternative to stimulated serum C‐peptide measurement in late‐onset, insulin‐treated diabetes. Diabetic medicine. 2011;28(9):1034-8. doi: https://doi.org/10.1111/j.1464-5491.2011.03272.x

8. Wang Y, Zou X, Cai X, et al. Urinary C‐peptide/creatinine ratio: a useful biomarker of insulin resistance and refined classification of type 2 diabetes mellitus. Journal of Diabetes. 2021;13(11):893-904. doi: https://doi.org/10.1111/1753-0407.13203

9. Alshamsi F, Pathan A, Yasin J, et al. Urinary C-peptide creatinine ratio as a non-invasive diagnostic tool for differentiating type 1 from type 2 diabetes mellitus in adult Emirati population: a prospective validation study. Front Endocrinol (Lausanne). 2025;16:1687920. doi: https://doi.org/10.3389/fendo.2025.1687920.

10. Irilouzadian R, Afaghi S, Esmaeili Tarki F, et al. Urinary c-peptide creatinine ratio (UCPCR) as a predictor of coronary artery disease in type 1 diabetes mellitus. Endocrinol Diabetes Metab. 2023;6(3):e413. doi: https://doi.org/10.1002/edm2.413

11. Consultation WE. Waist circumference and waist-hip ratio. Report of a WHO Expert Consultation Geneva: World Health Organization. 2008;2008:8-11

12. Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. Journal of health economics. 2008;27(2):519-29. doi: https://doi.org/10.1016/j.jhealeco.2007.05.005

13. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S252-S265. doi: https://doi.org/10.2337/dc25-S012

14. McDermott MM, Criqui MH, Liu K, et al. Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. Journal of Vascular Surgery. 2000;32(6):1164-71. doi: https://doi.org/10.1067/mva.2000.108640

15. Ziaee A, Esmailzadehha N, Oveisi S, et al. The threshold value of homeostasis model assessment for insulin resistance in Qazvin metabolic diseases study (QMDS): assessment of metabolic syndrome. J Res Health Sci 2015;15:94–100

16. American Diabetes Association Professional Practice Committee; 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care.2025; 48 (Supplement_1): S239–S251. doi: https://doi.org/10.2337/dc25-S011.

17. McDonald TJ, Knight BA, Shields BM, et al. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clinical chemistry. 2009;55(11):2035-9. doi: https://doi.org/10.1373/clinchem.2009.129312

18. Wang Y, Gao Y, Cai X, et al. Clinical implications of urinary C‐peptide creatinine ratio in patients with different types of diabetes. Journal of Diabetes Research. 2019;2019(1):1747684. doi: https://doi.org/10.1155/2019/1747684

19. Besser RE, Shields BM, Hammersley SE, et al. Home urine C‐ peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatric diabetes. 2013;14(3):181-8. doi: https://doi.org/10.1111/pedi.12008

20. Zhou W, Li J, Yuan X, et al. Application of urine C-peptide creatinine ratio in type 2 diabetic patients with different levels of renal function. Frontiers in Endocrinology. 2022;13:1052794. doi: https://doi.org/10.3389/fendo.2022.1052794

21. Bhosle D, Sayyed A, Bhagat A, Sheikh H, Londhe V. Homeostasis model assessment of insulin resistance (HOMA-IR) in the diagnosis of insulin resistance and prediabetes. J Med Sci Clin Res. 2016;4(9):12705-10. doi: https://doi.org/http://dx.doi.org/10.18535/jmscr/v4i9.65

22. Reintar S, Pöchhacker M, Obermayer A, et al. Urinary C-Peptide to Creatinine Ratio (UCPCR) as Indicator for Metabolic Risk in Apparently Healthy Adults—A BioPersMed Cohort Study. Nutrients. 2023;15(9):2073. doi: https://doi.org/10.3390/nu15092073

23. Oram RA, Rawlingson A, Shields BM, et al. Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ open. 2013;3(12):e003193. doi: https://doi.org/10.1136/bmjopen-2013-003193

24. Gedam M, Sarma D, Choudhury B. Urinary C-peptide Creatinine Ratio and Its Correlation with Parameters of Metabolic Syndrome. Journal of Endocrinology Research. 2021;3(2):1-9. doi: https://doi.org/10.30564/JER.V3I2.3451

25. Hassan AA, Elshall S, Erfan A, et al. Urinary C-peptide and urinary C-peptide creatinine ratio as markers for insulin resistance in obese children and adolescents. Pediatric Research. 2022;92(3):805-9. doi: https://doi.org/10.1038/s41390-021-01847-2

26. Farghaly HS, Metwalley KA, Gamal Y, Saied GM, Farouk Y. Urinary C-peptide creatinine ratio is a significant indicator of non-alcoholic fatty liver disease in children with obesity. The Turkish Journal of Pediatrics. 2022;64(3):482-9. doi: https://doi.org/10.24953/turkjped.2022.41

27. Kulkarni C, Patil S. Urinary C-Peptide and urine C-pentide/ Creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects-a randomized study. 2016. doi: https://doi.org/10.22376/IJPBS.2016.7.4.B443-446

28. Elzahar W, Arafa A, Youssef A, Erfan A, El Amrousy D. Urinary C-peptide creatinine ratio to differentiate type 2 diabetes mellitus from type 1 in pediatric patients. European Journal of Pediatrics. 2020;179:1115-20. doi: https://doi.org/10.1007/s00431-020-03606-7


About the Authors

Y. M. Eman
Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University
Egypt

Eman Y. Morsy, PhD, Professor 

Alexandria 


Competing Interests:

The authors declare no obvious and potential conflicts of interest related to the content of this article.



G. A. Noha
Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University
Egypt

Noha G. Amin, PhD, Professor 

Alexandria 


Competing Interests:

The authors declare no obvious and potential conflicts of interest related to the content of this article.



A. I. Yasmine
Associate Professor of Medical Biochemistry, College of Medicine, Arab Academy of Science, Technology and Maritime Transport
Egypt

Yasmine A. Issa, PhD, Professor

New Alamein  


Competing Interests:

The authors declare no obvious and potential conflicts of interest related to the content of this article.



K.A.K. Rowan
Department of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University
Egypt

Rowan K.A. Khalifa, MD, Doctor 

Alexandria


Competing Interests:

The authors declare no obvious and potential conflicts of interest related to the content of this article.



S. K. Heba
Assistant Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University
Egypt

Heba S. Kassab, MD PhD, Assistant Professor 

Web of Science Researcher ID: GRT-0147 -2022; Scopus ID: 57188661935

17 Champollion Street, El Messallah, Alexandria, postcode 21131 


Competing Interests:

The authors declare no obvious and potential conflicts of interest related to the content of this article.



Supplementary files

1. Figure 1: Correlation between UCPCR with HOMA-IR (n=90)
Subject
Type Исследовательские инструменты
View (237KB)    
Indexing metadata ▾
2. Figure 2: ROC curve for UCPCR to discriminate HOMA-IR ≥2.5 (n=47 vs. 43)
Subject
Type Исследовательские инструменты
View (166KB)    
Indexing metadata ▾

Review

For citations:


Eman Y.M., Noha G.A., Yasmine A.I., Rowan K., Heba S.K. Urinary C Peptide/ Creatinine Ratio Is Related to Insulin Resistance but Not Vascular Complications In Type 2 Diabetes. Obesity and metabolism. 2026;23(2):61-66. https://doi.org/10.14341/omet13246

Views: 90

JATS XML

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)